Emerald Health Pharmaceuticals

Synthetic CBD Derivative Based Drug For Systemic Sclerosis Phase 2a Trial Enters Final Stage

Emerald Health Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing a new class of medicines to treat neurodegenerative, autoimmune and other diseases, has received a positive safety review following a pre-specified interim analysis by the Safety review committee (“SRC”) of its phase 2

SEC Charges 6 Individuals, 2 Companies For Cannabis Stock Promotion Scheme

On September 30, the Securities and Exchange Commission (SEC) announced that it had charged 6 individuals and 2 companies for the involvement in a stock promotion scheme that included Emerald Health Pharmaceuticals, Elegance Brands Inc.